| Patient | Vivekananda |
|---|---|
| Date of birth | 1991-01-12 |
| Identifiers | MRN HR-NI032-SYN; SSN (made up) 000-32-9014 |
| Document date | 2026-03-23 |
| Author | Anjali Thornbury-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-week diabetes review before a long journey. [S]
Swami Vivekananda returns five weeks after starting metformin and two weeks after starting losartan. His thirst has gone, he wakes to pass urine once a night or not at all, and his fasting readings are 128 to 150 mg/dL. He has had no dizziness on losartan; home blood pressure averages 128/80. He has seen the dietitian twice: he now takes a smaller portion of rice with more dal and vegetables, keeps the sweets offered after worship to a small piece, and has kept two fortnightly fasts with fruit, milk and water, with midday readings of 110 to 140 mg/dL. The screening tests from the preventive visit were negative for HIV, hepatitis C, hepatitis B surface antigen and tuberculosis infection, and he is not immune to hepatitis B. He has decided to take the statin. In a week he leaves for several months of travel and teaching in the mountains, and wants a plan he can follow far from the clinic. [S]
| Element | Detail |
|---|---|
| Glucose | Fasting 128 to 150 mg/dL; midday on fast days 110 to 140 mg/dL |
| Blood pressure | Home average 128/80 on losartan |
| Screening results | HIV, hepatitis C antibody, hepatitis B surface antigen and interferon-gamma release assay negative; hepatitis B surface antibody negative |
| Upcoming | Several months of travel in the mountains from next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy much better; weight 73.8 kg |
| Genitourinary | Negative | Nocturia once at most |
| Gastrointestinal | Negative | No loose stools |
| Psychiatric | Negative | Eager for the journey; sleep still slow to come |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week | 1000 mg with the evening meal | Oral route | 2026-02-16 to 2026-03-23 | completed | S |
| Metformin extended-release 500 mg tablets: four tablets (2000 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink | 2000 mg with the evening meal | Oral route | 2026-03-23 | active | S |
| Losartan 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Atorvastatin 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-23 | Body height | 172 | cm | S |
| 2026-03-23 | Body weight | 73.8 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 24.9 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 74 | /min | S |
| 2026-03-23 | Respiratory rate | 14 | /min | S |
| 2026-03-23 | Body temperature | 36.6 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-23 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-23 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-23 | Albumin/Creatinine [Mass Ratio] in Urine | 41 | mg/g | 30 to 299 moderately increased; 300 or more severely increased | High | S |
Vital signs recorded on 2026-03-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 73.8 kg; blood pressure 128/80, pulse 74 |
| Eyes | Retinal photographs today: no retinopathy in either eye |
| Cardiovascular | Regular; no edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptide | resolved | confirmed | R73.9 | S — Synthetic presenting problem anchored to his documented diabetes of the year before. Superseded by the diagnosis at the second visit. |
| Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetes | active | confirmed | E11.65 | S — Synthetic modern confirmation and classification linked to his documented diabetes. |
| Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six months | active | confirmed | R80.9 | S — Synthetic finding linked to his documented albuminuria; superseded when diabetic kidney disease was confirmed. |
| Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be taken | resolved | confirmed | R03.0 | S — Synthetic finding; not a claim about his real blood pressure. |
| Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetes | active | confirmed | I10 | S — Synthetic finding of the modern episode; not a claim about his real blood pressure, which was never recorded. |
| Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditation | active | confirmed | G47.00 | S — Synthetic modern problem linked to his documented lifelong difficulty falling asleep. |
| Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36 | active | confirmed | E78.2 | S — Synthetic cardiovascular risk factor. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | A1c | Quarterly until at goal and after a change in therapy | Due | Due in three months, during his travels; arrangements made |
| Laboratory | Potassium and creatinine after starting an ARB | One to two weeks after starting or changing the dose | Completed today | Potassium 4.6; creatinine 1.00; eGFR 101 |
| Laboratory | Urine albumin-to-creatinine ratio | Two of three abnormal over three to six months to confirm | Completed today | 41 mg/g, the second abnormal sample |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting | Due | Statin started today; due in six to twelve weeks |
| Imaging | Retinal photographs | At diagnosis, then every one to two years | Completed today | No retinopathy in either eye |
| Examination | Blood pressure, weight and BMI | Every visit | Completed today | 128/80; home 128/80; weight 73.8 kg |
| Self-management | Medical nutrition therapy | At diagnosis and as needed | Completed today | Two dietitian visits; a mostly vegetarian plan of his choosing |
| Self-management | Fasting plan | Before any religious fast | Completed today | Fasts with fruit, milk and water went safely; travel rules agreed |
| Self-management | Sick-day rules | At diagnosis and before travel | Completed today | Hold metformin and losartan when vomiting, diarrhea or unable to drink |
| Self-management | Tobacco use | Every visit | Completed today | None |
| Self-management | Insomnia treatment | At diagnosis of chronic insomnia | Referred | Cognitive behavioral therapy for insomnia by video |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, CKD and asthma monographs (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); Hassanein M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract 2022;185:109185 (PMID 35016991) (2021)
Follow-up: Messages with home readings monthly while he travels. A1c, urine albumin and lipid panel in about three months wherever he is. Diabetes review on his return. Next scheduled visit 2026-10-27: review after seven months away and a week after an asthma attack: A1c, kidneys, lipids, spirometry with bronchodilator response and FeNO; asthma and diabetic kidney disease confirmed; empagliflozin and maintenance-and-reliever inhaler; fasting plan for the coming festival. [S]